SMMT Summit Therapeutics Inc

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces that Mr Glyn Edwards, Chief Executive Officer, will present on the Company’s plans to advance its new mechanism antibiotic pipeline at the Rodman & Renshaw 20th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, 6 September 2018 at 11:15am EDT in New York City.

A live webcast of the presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.

About Summit TherapeuticsSummit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office)		Tel:		44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office)				+1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser)		Tel:		+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker)		Tel:		+44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
Panmure Gordon (Joint Broker)		Tel:		+44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
James Stearns, Corporate Broking
MSL Group (US)		Tel:		+1 617 684 6557
Jon Siegal				Jon.siegal@mslgroup.com
Consilium Strategic Communications (UK)		Tel:		+44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson				summit@consilium-comms.com
/ Lindsey Neville